Skotak v. Tenneco Resins, Inc.

CourtCourt of Appeals for the Fifth Circuit
DecidedMay 20, 1992
Docket90-1256
StatusPublished

This text of Skotak v. Tenneco Resins, Inc. (Skotak v. Tenneco Resins, Inc.) is published on Counsel Stack Legal Research, covering Court of Appeals for the Fifth Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Skotak v. Tenneco Resins, Inc., (5th Cir. 1992).

Opinion

IN THE UNITED STATES COURT OF APPEALS

FOR THE FIFTH CIRCUIT

______________________

No. 90-1256 ______________________

MARY FAYE SKOTAK, GEORGE JERRY SKOTAK, and ERIC NORMAN SKOTAK,

Plaintiffs-Appellants- Cross-Appellees,

v.

TENNECO RESINS, INC.,

Defendant-Appellee- Cross-Appellant.

______________________________________________________________

Appeal from the United States District Court for the Northern District of Texas ______________________________________________________________ ( March 26, 1992)

ON SUGGESTION FOR REHEARING EN BANC

Opinion February 3, 1992, 5 Cir., 1992, 953 F.2d 909

Before WISDOM, KING and BARKSDALE, Circuit Judges.

PER CURIAM:

Treating the suggestion for rehearing en banc as a petition

for panel rehearing, it is ordered that the petition for panel

rehearing is DENIED. No member of the panel nor Judge in regular

active service of this Court having requested that the Court be

polled on rehearing en banc (Federal Rule of Appellate Procedure

and Local Rule 35), the suggestion for Rehearing En Banc is DENIED.

The three February 3, 1992, opinions are revised as follows: BARKSDALE, Circuit Judge:

Paragraph II.B. of my original opinion is withdrawn.

KING, Circuit Judge, concurring in the judgment:

I withdraw my original opinion and concur in the judgment

without opinion.

WISDOM, Senior Circuit Judge, dissenting:

I withdraw my original dissenting opinion and substitute the

following opinion:*

I respectfully dissent.

Judge Barksdale, for the majority of the Court, holds that the

plaintiffs failed to show that there was a genuine issue for trial

with respect to the adequacy of the manufacturer's warning of the

risk of cancer from using Thorotrast.

The plaintiffs introduced in the record copies of two

scientific articles and a letter to the Editor of Cancer bearing on

the relationship between cancer and Thorotrast.

a. Article 1: Underwood & Hall, Thorotrast Associated Hepatic Angiosarcoma with 36 Years Latency, Cancer 42: 2610-12 (Dec. 1978);

b. Letter to editor, Thorium Dioxide and Liver Cancer, JAMA, Vol. 246, No. 16 (Oct. 16, 1981); and

c. Article 2: Benjamin & Albukerk, Thorotrast- Induced Angiosarcoma of Liver, N.Y. State J. Med., pp. 751-53 (Apr. 1982).

* I have incorporated in this opinion a large part of the opinion Judge King withdrew.

2 Article 1 referred to an April 1925 study (not introduced in the

record) entitled "Some unrecognized dangers in the use and handling

of radioactive substances". JAMA 85:1769-1776 (1925). The same

article noted that in 1932 the American Medical Association's

Council on Pharmacy and Chemistry disapproved of Heyden's

introduction of Thorotrast into the United States. Both Articles

1 and 2 referred to a 1947 report in the American Journal of

Pathology by McMahon, E., Murphy, A.S., and Bates, M.J., (not

introduced in the record) documenting the link between cancer and

Thorotrast. The report stated that the use of Thorotrast

noticeably declined in the 1950's and continued to decline. The

plaintiffs' attorney inartfully attached the articles as exhibits

to the Skotaks' opposition to a motion to dismiss for lack of

personal jurisdiction, apparently as part of the description of the

"background" of their lawsuit. The Skotaks did not suggest the

relevancy of the articles before or when TRI moved for summary

judgment and did not assert the importance of the articles until

they filed their reply brief in this court. It would seem likely

that the Skotaks' attorney expected to introduce the articles in

the trial on the merits. Nevertheless, they were in the record.

We should consider the record as a whole in determining whether

there was a dispute over a material fact.

Judge Barksdale would have the Court ignore these articles.

Based on the articles, a reasonable jury could make the

following findings:

(1) Thorotrast is a radioactive contrast medium first developed and used in Germany in the 1920's.

3 (2) The relationship between radioactive chemicals and cancer was documented in a 1925 article by Martland, H.S., Conlan, P., and Knef, J.P. in the Journal of the American Medical Association entitled "Some Unrecognized Dangers in the Use and Handling of Radioactive Substances". JAMA 85:1769-1776 (1925).

(3) In 1932, based primarily on the findings of Martland, H.S., Conlan, P., and Knef, J.P. the American Medical Association's Council on Pharmacy and Chemistry disapproved of the introduction of Thorotrast in the United States.

(4) The relationship between Thorotrast and liver cancer was documented in a 1947 article by McMahon, E., Murphy A.S., and Bates, M.J., "Endothelial Cell Sarcoma of the Liver Following Thorotrast Injections". Am. J. Pathology, 23:586-611 (1947).

(5) Following the 1947 findings, a large number of reports surfaced linking cancer with previous administration of Thorotrast.

(6) As a result of these reports, the use of Thorotrast as a contrast medium quickly decreased, and by the mid- 1950's Thorotrast was no longer used in the United States as a contrast medium.

This information would permit a jury to find that either of the

possible warnings (quoted in Judge Barksdale's opinion) would have

been inadequate for failing to mention the evidence linking

radioactive chemicals and cancer, and for failing to mention

McMahon's finding, of a link between Thorotrast and liver cancer.

Even though the testimony of the actual treating physician is

unavailable, the timing of the marked decline in Thorotrast use

following the release of information on the cancer risk would

permit a reasonable jury to infer: (1) that most physicians were

unaware of the cancer risks associated with Thorotrast before the

information was released; and (2) once they became aware of the

cancer risk, the vast majority of physicians switched to a

4 substitute contrast medium. In the absence of specific evidence of

the treating physician's actual knowledge and likely response, a

jury could reasonably infer that Mr. Skotak's treating physician

was likely to have the same information available, and would

respond in the same manner, as the vast majority of physicians.

The articles, therefore, raise a genuine issue of material fact

with respect to the adequacy of the warning.

The result reached by Judge Barksdale is contrary to our

holdings in Higgenbotham v. Ochsner Foundation Hospital,1 Keiser v.

Coliseum Properties, Inc.,2 and Nicholas Acoustics & Specialty Co.

v. H & M Constr. Co.3 In those cases we held that, at least where

the record is small (as it is in this case), a reviewing court must

consider the entire record in determining whether there is a

genuine issue of material fact.4 Although, except for

Higgenbotham, Fifth Circuit cases touching on this question are not

models of clarity, I conclude, unlike Judge Barksdale, that in the

1 607 F.2d 653 (5th Cir. 1979).

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
Skotak v. Tenneco Resins, Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/skotak-v-tenneco-resins-inc-ca5-1992.